Header Logo

MONICA CHEN

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Anesthesiology
Address6621 FANNIN
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mandal? M, Chen MF, Sullivan RJ, Sergi MC, Postow M, Lawless AR, Effiom D, Peres T, Lorigan PC, Serra-Bellver P, Dummer R, Amaral T, Rasch ML, Giannarelli D, Vitale MG, Helgadottir H, Robert C, Ubaldi M, Johnson DB, Del Vecchio M, Indini A, Suijkerbuijk KPM, Nathan P, Carter T, Neyns B, Dirven I, Pires da Silva I, Menzies AM, Zimmer L, Livingstone E, Depenni R, K?hler K, Hauschild A, Spagnolo F, Di Giacomo AM, Arance A, Merelli B, Quaglino P, Rossi E, Tucci M, Guida M, Mu?oz-Couselo E, Long GV, Larkin J, Ascierto PA. Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases. J Immunother Cancer. 2026 May 04; 14(5). PMID: 42082273; PMCID: PMC13141176.
      Citations:    Fields:    Translation:Humans
    2. Chen MF, Lee JJ, Choudhury NJ, Hui AB, Jeng MY, Zheng J, Aly RG, Sielski N, Ahn L, Pupo A, Nesselbush MC, Jabara I, Wilcox JA, Santomasso BD, Lin AL, Schaff L, Chaft JE, Riely GJ, Kris MG, Arfe A, Yang SR, Young RJ, Diehn M, Boire A, Yu HA. Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 03; 21(3):103505. PMID: 41139066.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Di Federico A, Wang K, Chen MF, Barsouk AA, Pagliaro A, Chen LN, Ogliari FR, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton GM, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi JV, Pecci F, Gelsomino F, Corassa M, Vokes NI, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad MM, Pabani A, Murray JC, Cappuzzo F, Garassino MC, Dagogo-Jack I, Riely G, Grant M, Herzberg BO, Ardizzoni A, Planchard D, Johnson BE, Langer CJ, Offin M, Negrao MV, Ricciuti B. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol. 2025 Oct; 26(10):1357-1369. PMID: 41038185.
      Citations: 3     Fields:    Translation:Humans
    4. Chen MF, Jeng MY, Ma J, Agrawal P, Dunne E, Boe LA, Kris MG, Huang J, Veeraraghavan H, Gomez D, Yu HA. Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precis Oncol. 2025 May; 9:e2500047. PMID: 40373257; PMCID: PMC12088374.
      Citations: 2     Fields:    Translation:Humans
    5. Lochrin SE, Kalvin HL, Smithy JW, Chen MF, Momtaz P, Shoushtari AN, Panageas KS, Postow MA. Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy. JAMA Oncol. 2025 Mar 01; 11(3):349-351. PMID: 39883427; PMCID: PMC11783241.
      Citations:    
    6. Chen MF, Yang SR, Tao JJ, Desilets A, Diamond EL, Wilhelm C, Rosen E, Gong Y, Mullaney K, Torrisi J, Young RJ, Somwar R, Yu HA, Kris MG, Riely GJ, Arcila ME, Ladanyi M, Donoghue MTA, Rosen N, Yaeger R, Drilon A, Murciano-Goroff YR, Offin M. Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets. Clin Cancer Res. 2024 Sep 03; 30(17):3812-3823. PMID: 38922339; PMCID: PMC11371517.
      Citations:    
    7. Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel VK, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist RS, Iqbal S, Gandhi N, Elliott A, Vanderwalde AM, Ma PC, Halmos B, Liu SV, Che J, Schrock AB, Drilon A, J?nne PA, Awad MM. Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors. Cancer Discov. 2024 Aug 02; 14(8):1440-1456. PMID: 38564707; PMCID: PMC11294820.
      Citations:    
    8. Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 Apr; 8:e2300454. PMID: 38591867; PMCID: PMC10896470.
      Citations:    
    9. Thummalapalli R, Choudhury NJ, Ehrich F, Beardslee T, Brazel D, Zhang SS, Merchant S, Chen MF, Heller G, Ramalingam SS, Ou SI, Mileham KF, Riely GJ. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK-?or ROS1-Rearranged NSCLC: A Brief Report. JTO Clin Res Rep. 2023 Aug; 4(8):100546. PMID: 37644967; PMCID: PMC10460990.
      Citations:    
    10. Chen MF, Yang SR, Shia J, Girshman J, Punn S, Wilhelm C, Kris MG, Cocco E, Drilon A, Raj N. Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors. JCO Precis Oncol. 2023 05; 7:e2200697. PMID: 37262390; PMCID: PMC10309517.
      Citations:    
    11. Chen MF, Chaft JE. Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review. Transl Lung Cancer Res. 2023 Feb 28; 12(2):337-345. PMID: 36895922; PMCID: PMC9989809.
      Citations:    
    12. Kamel H, Alwell K, Kissela BM, Sucharew HJ, Woo D, Flaherty M, Ferioli S, Demel SL, Moomaw CJ, Walsh K, Mackey J, De Los Rios La Rosa F, Jasne A, Slavin S, Martini S, Adeoye O, Baig T, Chen ML, Levitan EB, Soliman EZ, Kleindorfer DO. Racial Differences in Atrial Cardiopathy Phenotypes in Patients With Ischemic Stroke. Neurology. 2021 Feb 22; 96(8):e1137-e1144. PMID: 33239363; PMCID: PMC8055350.
      Citations: 2     Fields:    
    13. Morris NA, Chen ML, Adejumo OL, Murthy SB, Kamel H, Merkler AE. Stroke Risk Following Takotsubo Cardiomyopathy. Neurohospitalist. 2020 Oct; 10(4):277-280. PMID: 32983346; PMCID: PMC7495697.
      Citations:    
    14. Witsch J, Merkler AE, Chen ML, Navi BB, Sheth KN, Freedman B, Schwamm LH, Kamel H. Incidence of Atrial Fibrillation in Patients With Recent Ischemic Stroke Versus Matched Controls. Stroke. 2018 10; 49(10):2529-2531. PMID: 30355110; PMCID: PMC6205716.
      Citations:    
    15. Chen ML, Gupta A, Chatterjee A, Khazanova D, Dou E, Patel H, Gialdini G, Merkler AE, Navi BB, Kamel H. Association Between Unruptured Intracranial Aneurysms and Downstream Stroke. Stroke. 2018 09; 49(9):2029-2033. PMID: 30354970; PMCID: PMC6205209.
      Citations:    
    CHEN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (67)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _